234 results about "Cell phenotype" patented technology

The present invention provides a non-mouse, including human, pluripotential embryonic stem cell which can:

• • (a) be maintained on feeder layers for at least 20 passages; and
  • (b) give rise to embryoid bodies and multiple differentiated cell phenotypes in monolayer culture.

The invention further provides a method of making a pluripotential embryonic stem cell comprising culturing germ cells and germ cell progenitors in a composition comprising a growth enhancing amount of basic fibroblast growth factor, leukemia inhibitory factor, membrane associated steel factor, and soluble steel factor to primordial germ cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.

Also provided are compositions useful to produce the pluripotent embryonic stem cells and methods of screening associated with the method of making the embryonic stem cell.

The invention relates to the field of biology, and discloses a serum-free culture medium which essentially comprises an IMDM (Iscove Modified Dulbecco Medium), L-glutamine, sodium bicarbonate, Hepes, recombinant human insulin, recombinant human transferrin, recombinant human albumin, 2-mercaptoethanol, protocatechuic acid, lipid, amino acid, vitamins, trace elements, Pluronic F-68, hydrocortisone, vitamin C, bonding amine or recombinant human fibronectin, progesterone, putrescine, heparin, serotonin, epidermal growth factors (EGFs), b-fibroblast growth factors (FGF), platelet derive growth factor (PDGF)-BB and insulin-like growth factor (IGF)-I. The serum-free culture medium is clear in chemical components, free from animal sources and serum and safe and ideal in cell cultivation and avoids the doped animal components and unstable batches, and the results of the cultured mesenchymal stem cells show that the total cellular score, the cell phenotype and the secretory cell factors are normal, so that the serum-free culture medium has good industrial application prospect.

The invention relates to a method for treating, controlling, or preventing cancerous cell phenotypes and growths in an animal involving the administration of gaseous nitric oxide to one or administration sites in a body. The invention generally is capable of treating cancers found in or on the adrenal gland, bladder, bones, brain, breast, cervix, colon, colorectum, esophagus, gastrointestinal tract, heart, kidney, liver, large intestine, lungs, mouth, ovaries, pancreas, parathyroid, pituitary gland, prostate, salivary gland, skin, small intestine, spleen, stomach, thymus, thyroid, testicles, urinary tract, uterus, vagina, and so forth.

The present invention provides a microorganism culture array, including one or more microflow cell culture array units, the microflow cell culture array unit includes a main channel and a plurality of cell culture units connected with the main channel, each culture unit includes a diffusion channel and a cell culture room, the cell culture room is connected with the main channel. The microorganism culture array of the invention not only realizes isolation of single-cell, but also makes the cell locate in zero flow state when the culture liquid or other reagent is changed, bringing greatly convenience for the cell culture and observation especially the culture and observation of non-adherent cells, greatly fit for research work of high throughput screen based on the cell phenotype.

Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, fgfr-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies.

Isolated human cells and populations thereof are provided comprising at least one oligodendrocyte phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an oligodendrocyte phenotype. Methods of generating and using same are also provided.

The invention belongs to the technical field of stem cells, and particularly relates to a serum-free medium for culturing a mesenchymal stem cell. According to the serum-free medium, a basal culture medium L-DMEM or DMEM/F12 and multiple additives are combined in a customized manner for MSCs in vitro culture, so that ingredients in the culture medium are synergized; the stability and success rate for culturing MSCs in vitro can be greatly improved especially due to application of DKK-1; and the safety of cultured cells in clinical researches is improved by adopting a formula without animal-sourced ingredient. Compared with the prior art, the serum-free medium has the advantages of greatly improving the value adding efficiency of MSCs in vitro culture and maintaining cell growth form of MSCs and cell phenotype stability thereof, provides a novel efficient, stable and safety culture system to MSCs culture in clinical application, and has high scientific researching and medical application values.

The present invention provides methods for systematically identifying genes, proteins and/or related pathways that regulate or indicative of cell phenotypes. The present invention further provides methods for manipulating the identified genes, proteins and/or pathways to engineer improved cell lines and/or to evaluate or select cell lines with desirable phenotypes.

The invention relates to a microfluidic diffusion and open intervening cell culture array chip and a fabrication method and application thereof. The cell culture array chip is suitable for cell culture, stem cell proliferation, drug screening, regenerative medicine and the like. The cell culture array chip comprises a base and a substrate fixed on the base, wherein a plurality of hole-like cell culture unit are distributed on the substrate; and a microfluidic main channel and a microfluidic diffusion channel, which are intercommunicated with each other, are arranged on the substrate and are communicated with each cell culture unit and the external environment. The cell culture array chip provided by the invention has the following advantages: (1) the required culture solution, growth factors and the like are supplied through a microfluidic diffusion network, so as to result in a zero cell shearing force and ensure the gas and moisture environment required for cell growth; (2) the in vivo microenvironment multichannel microfluidic concentration gradient of cells is simulated, and the quantitative drug release at a fixed time and other functions are realized; (3) the chip is suitable for high-throughput drug screening research on cell phenotype; and (4) the chip has a compact structure and low cost, and is suitable for batch production.

A novel classification system for breast cancer based on normal breast cell phenotypes and various expression levels of estrogen receptor (ER), androgen receptor (AR), and vitamin D receptor (VDR). The various categories of the classification system are associated with different survival rates and prognoses. The invention includes a method of classifying breast cancer comprises measuring the levels of ER, AR, and VDR in the cancerous tissue, and classifying the breast cancer into one of the above-noted categories according to expression levels. The invention includes a method of predicting the prognosis of breast cancer in a patient and a method of determining a treatment regimen for breast cancer depending on the category in which the breast cancer is classified. The invention includes a method of treating breast cancer according to the expression profile of ER, AR, and VDR detected in the cancerous tissue. Kits for detecting the same are also provided.

Specular, ultrasonic, piezoelectric, detection devices provide real-time, analytical, edge finding in tissues during tumor surgery. Piezoelectric probe sensors at high frequencies (e.g., 10 to 100 MHz) characterize microstructure of cells and tissues. Through-transmission or specular reflection enables nondestructive testing in real time. Peak density analysis in power spectra, second-order spectrum analysis measuring the slope of the Fourier transform of the power spectrum, artificial intelligence pattern recognition, and modeling interpret the results. Model-based data analysis may compare experimental data with a computer simulation. Such comparisons may be based upon pattern classifications, including principal component analysis (PCA). Combining the above detection devices and analytical methods provides speed, accuracy, simplicity, and nondestructive mechanisms that militate for reliable, real-time diagnosis of tumor margins, tissue pathology, cell phenotypes, and molecular subtypes.

A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharamaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis and vasculogenesis inducing factors. Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the angiogenesis and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair.

The invention belongs to the field of cell therapy, and especially relates to an animal derived serum-free cell freezing medium. The animal derived serum-free cell freezing medium comprises, by volume, 5-15% of human albumin, 5-15% of dimethyl sulfoxide and 70-90% of hydroxyethyl starch. The cell freezing medium contains no animal derived serum, so no exogenous proteins are introduced, and the animal pathogen pollution possibility is reduced; and the animal derived serum-free cell freezing medium is safe and effective in additional culture or clinic direct transfusion after cryopreservation resuscitation, and also has the advantages of simple preparation method, low cost and good clinic application prospect. The activity of recovered cells reaches about 90%, and the cell phenotype basically has no change, so the physiologic functions and the biological functions of the recovered cells are kept. The animal derived serum-free cell freezing medium is suitable for refrigerated storage of mononuclear cells and other various cells.

The invention relates to a tissue engineering meniscus repair sheet and a preparation method thereof. The prepared tissue engineering meniscus repair sheet comprises an acellular meniscal thin sheet, seed cells and growth factor slow-release carriers, wherein blind micro vias are uniformly distributed on two surfaces of the acellular meniscal thin sheet, and the seed cells and the growth factor slow-release carriers are combined on two surfaces of the acellular meniscal thin sheet. The blind micro vias distributed on the acellular meniscal thin sheet increase the area of a support material, and can be used as a storage pool of the seed cells and the growth factor slow-release carriers, so that the seed cells and the growth factor slow-release carriers can be firmly attached and are not easy to fall off. Nutrition can be persistently released through the slow-release carrier by multiple growth factors, the cell amplification efficiency is improved, the cell phenotype is also maintained, cell ageing is inhibited, and fusion of the tissue engineering meniscus repair sheet and self tissue is promoted. The prepared tissue engineering meniscus repair sheet has the structure characteristic similar to the structure characteristic of natural meniscus, and is applicable to repair meniscus injure and induce regeneration of meniscus fibrous cartilage tissue.

The invention relates to genetic engineering bacteria capable of producing pantothenic acid at high yield without addition of beta-alanine, a construction method of the genetic engineering bacteria, and application of the genetic engineering bacteria in preparation of D-pantothenic acid by microbial fermentation. According to the invention, (1), the final step of an escherichia coli D-pantothenicacid synthesis pathway is enhanced, and the utilizing ability of escherichia coli to extracellular beta-alanine, (2), a pantoic acid synthesis pathway is enhanced, (3), ilvG gene is repaired, and thefeedback inhibition effect of by-products on a pantoic acid synthesis pathway is weakened, (4), according to the change in cell phenotype, flux of a valine synthesis pathway is weakened, (5), a CRISPRi technique is used to screen metabolic modification sites of TCA cycle, a PPP pathway and a by-product metabolic pathway, according to the result, an isoleucine synthesis pathway is blocked, and thecompetition of 2-butanoic acid for reaction of acetolactate synthesized from pyruvic acid under catalysis of acetolactate synthase is relieved, and (6), aspartate decarboxylase from other strains is subjected to heterologous expression to obtain a genetical engineering strain capable of producing the pantothenic acid at high yield without addition of the beta-alanine. By combined expression of panB and panC which are derived from corynebacterium glutamicum and panD derived from bacillus subtilis together on pTrc99A plasmids, 1.2g/L of D- pantothenic acid is obtained without adding the beta-alanine.

A method of staining or pre-staining at least one cell is provided. The method comprising contacting the at least one cell with a staining agent selected from the group consisting of an extract of a Ficus elastica plant, a C₂₃H₄₄O₄ and a proanthocyanidin, thereby staining or pre-staining the at least one cell. Also provided are methods of detecting cells of different differentiation stages and methods of diagnosing cancer and metabolic diseases.

The present invention isolates and characterizes the exc-4 gene of C. elegans, and identifies exc-4 as an orthologue of the human CLIC family of chloride intracellular channels. Accordingly, a nucleic acid having the sequence of SEQ ID NO.: 1 is disclosed, as well as recombinant vectors and host cells comprising the nucleic acid sequence of SEQ ID NO.: 1. Further, a number of screening methods are disclosed to identify putative agents that inhibit vertebrate, and preferably human, CLICs using C. elegans and exc-4 inhibition as a loss-of-function model for CLIC activity. Also disclosed is a method of determining whether a specific member of the CLIC gene family is involved in tubulogenesis, where the rescue of a C. elegans exc-4 excretory cell phenotype via expression of a transgenic CLIC gene of interest indicates that the CLIC gene of interest is involved in tubulogenesis. Finally, a method is disclosed of identifying putative vertebrate, and preferably human, CLIC inhibitors using transgenic C. elegans exc-4 mutant embryos, where expression of the transgene yields a CLIC product that rescues the exc-4 mutant phenotype. Agents of interest resulting in a reversionary exc-4 mutant phenotype are putative agents that inhibit CLIC expression or function.